The vascular dose of rivaroxaban in antithrombotic treatment of atherosclerotic diseases. Characteristics of patient profiles deriving the greatest benefit from therapy Review article
Article Sidebar
Main Article Content
Abstract
The need to further improve the effectiveness of anticoagulant therapy in secondary prevention arises from the fact that even intensive antiplatelet treatment does not fully eliminate cardiovascular risk. The results of the COMPASS trial indicate that extending therapy with additional inhibition of selected stages of the coagulation cascade may significantly reduce the incidence of major cardiovascular events in appropriately selected patients. Current guidelines of the European Society of Cardiology emphasize the important role of the so-called ‘vascular’ dose of rivaroxaban used in combination with ASA. This approach results not only from the very good outcomes of the COMPASS trial, but also constitutes an important element of modern, comprehensive therapy aimed at maximizing the reduction of cardiovascular risk.
Article Details
Copyright by Medical Education. All rights reserved.
References
2. Olie RH, van der Meijden PEJ, Ten Cate H. The coagulation system in atherothrombosis: Implications for new therapeutic strategies. Res Pract Thromb Haemost. 2018; 2(2): 188-98.
3. Eikelboom JW, Connolly SJ, Bosch J et al.; COMPASS Investigators. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N Engl J Med. 2017; 377(14): 1319-30.
4. Anand SS, Caron F, Eikelboom JW et al. Major adverse limb events and mortality in patients with peripheral artery disease: the COMPASS trial. J Am Coll Cardiol. 2018; 71(20): 2306-15.
5. Fulcher J, O’Connell R, Voysey M et al.; Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet. 2015; 385(9976): 1397-405.
6. Collins R, Reith C, Emberson J et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016; 388(10059): 2532-61.
7. Ettehad D, Emdin CA, Kiran A et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta- analysis. Lancet. 2016; 387(10022): 957-67.
8. Yusuf S, Sleight P, Pogue J et al.; Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000; 342(3): 145-53.
9. Visseren FLJ, Mach F, Smulders YM et al.; ESC National Cardiac Societies; ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021; 42(34): 3227-337.
10. Marx N, Federici M, Schütt K et al.; ESC Scientific Document Group. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023; 44(39): 4043-140.
11. Vrints C, Andreotti F, Koskinas KC et al.; ESC Scientific Document Group. 2024 ESC Guidelines for the management of chronic coronary syndromes. Eur Heart J. 2024; 45(36): 3415-537.
12. Mazzolai L, Teixido-Tura G, Lanzi S et al.; ESC Scientific Document Group. 2024 ESC Guidelines for the management of peripheral arterial and aortic diseases. Eur Heart J. 2024; 45(36): 3538-700.